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Abstract 
Many studies show that systemic inflammation marker levels should be taken into account as a key factor 
causing extrapulmonary complications and progression of the disease. However, assessment of systemic 
inflammation severity is not always used in routine medical practice to determine the severity of COPD. 
Aim: Determine the severity of systemic inflammation by measuring serum SAA and CRP levels during 
the stable phase of the disease in COPD patients who received different treatments. 
Materials and Methods: We have examined 37 COPD patients. Patients examination included general 
clinical methods, questionnaires for detecting of severity of symptoms, detecting severity of systemic 
inflammation by measuring serum SAA and CRP levels. Patients were divided into two subgroups 
depending on the treatment which they received. Patients of both subgroups were screened twice – at 
baseline (visit 1) and three months after assignment of adequate standard therapy (visit 2). 
Results: If treated inadequately, COPD patients in the stable phase, regardless of severity of their 
condition, suffer from more intense symptoms, have more relapses over the previous year, and their 
systemic inflammation levels are higher than in patients who receive long-term therapy adequate to their 
COPD. Proper three-month COPD treatment helps improve the symptoms to the levels found in patients 
who receive longer adequate therapy. As soon as three months after initiation, correctly assigned COPD 
treatment helps reduce systemic inflammation significantly by CRP levels and slightly by SAA levels. 
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1. Introduction 
The key objective of COPD patient management is to achieve long-term stabilisation of the 
disease and to slow down the progression of symptoms, life-threatening complications and 
rapid decline in quality of life [8, 9]. This can be achieved by timely prescription of basic 
medication therapy taking into account the severity of the condition [4, 6]. 
A comprehensive assessment recommended by the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) is important to monitor the efficacy of COPD treatment. [8]. Many 
studies show that systemic inflammation marker levels should be also taken into account as a 
key factor causing extrapulmonary complications and progression of the disease [6, 10]. 
However, assessment of systemic inflammation severity is not always used in routine medical 
practice to determine the severity of COPD.  
It should be noted that even in the stable phase of the pathological process systemic 
inflammation markers are elevated in COPD patients compared to healthy individuals, 
however, these markers can return to normal due to the treatment adequate to the severity of 
the condition [1, 2, 3, 11, 13]. There are publications of studies that assessed changes in systemic 
inflammation marker levels during exacerbation and after stabilisation of the condition, yet 
only a small number of the studies investigated changes in systemic inflammation markers 
during the stable phase of the disease in patients who received different treatments [4, 5, 6]. 
A large number of systemic inflammation markers are currently being studied in COPD 
patients but C-reactive protein (CRP) remains the best studied and accessible marker in 
clinical practice [3, 10]. Researchers are also interested in another, less well understood COPD 
systemic inflammation biomarker known as serum amyloid A (SAA) protein [11, 12, 13]. 
Therefore, our study was aimed to determine the severity of systemic inflammation by 
measuring serum SAA and CRP levels during the stable phase of the disease in COPD patients 
who received different treatments. 
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2. Materials and Methods 
We have examined 37 COPD patients (all patients had stage 
II-IV disease) in a stable pathological process phase 
(33 (89,18%) men, 4 (10,82%) women; mean age was 
63,45±1,18 years, level of forced expiratory volume in one 
second (FEV1) was 46,65 [42,00‒61,45] % pred. 
Patients were divided into two subgroups depending on the 
treatment which they received: subgroup 1–20 patients, who 
receiving adequate basic therapy for a long period of time 
(according to the severity of COPD in accordance with 
national standards [9]) (men – 18 (92%), women – 2 (8%), the 
average age was 63,22 ± 1,18 years, FEV1 – 46.30 [41,00-
63,60]% pred., number of exacerbations in the past year was 
1 [1–2]). Sub-group 2 consisted of 17 patients who did not 
receive adequate therapy (did not take medications on a 
regular basis, or were taking them in inadequate doses), 
(males was 15 (92%), women–2(8%) (p = 0.863 vs subgroup 
1) Average age was 64, 21 ± 1,88 year (p = 0.734 vs 
subgroup 1), FEV1 – 40.50 [35,85-49,50]% pred. (p = 0,612 
vs subgroup 1) number of exacerbations in the past year was 
2 [1-2] (p = 0,033 vs subgroup 1). 
Clinical diagnosis of COPD was formulated in accordance 
with Order No.555 of the Ministry of Health of Ukraine dated 
June 27, 2013 [9]. 
All patients were in a stable phase of COPD for at least two 
previous months.  
All patients signed informed consent forms for participation 
in the study.  
Patients of both subgroups were screened twice – at baseline 
(visit 1) and three months after assignment of adequate 
standard therapy (visit 2). 
Patients examination of both subgroups included general 
clinical methods (review of complaints, case history, life 
history), assessment of clinical symptoms. To assess dyspnea 
severity we used the modified British Medical Research 
Council (mMRC) scale recommended for COPD patients and 
containing 5 grades of dyspnea [8, 9]. The global effects of the 
disease on patient’s daily life were measured with the 8-items 
COPD Assessment Test (CAT) with possible total score from 
0 to 40. For symptoms assessment we also used St. George's 
Respiratory Questionnaire (SGRQ) (domain ‘symptoms’) [7].  
Pulmonary ventilation function was assessed with a morning 
fasting computer-based spirometry study by using Master 
Screen Body/Diff system (Jager, Germany). Levels of forced 
expiratory volume in one second (FEV1) and forced vital 
capacity (FVC) as percentage of the predicted value as well as 
the FEV1/FVC ratio were calculated. Reversibility of 
bronchial obstruction was measured by the change in FEV1 
absolute value (mL) after inhalation of 400 g of a short-
acting β2-agonist (salbutamol).  
Plasma C-reactive protein (CRP) (mg/L) was measured as a 
systemic inflammation marker by immunoturbidimetric 
technique. Values of SAA, other systemic inflammation 
marker, was analyzed in duplicate using a sandwich enzyme 
immunoassay kit (HK333, Human SAA Hycultbiotech 
(Netherlands)).  
During visit 1 COPD treatment was corrected to patients of 
subgroup 2 in accordance with the severity of COPD and 
national standards. [9] We did not change therapy to patients of 
subgroup 1 because their treatment was corresponded with 
disease severity. 
For statistical analysis of the results we used biometric 
analysis methodology supported by STATISTICA 6.1 
software. Normal distribution was analysed by the mean value 
and mean error while non-normal distribution was analysed 
by the median and quartiles (Me [25–75]). 
 
3. Results and Discussion 
The data analysis showed that patient groups were 
comparable in their age and gender at Visit 1 though there 
were significantly lower relapse rates in subgroup 1 over the 
past year, which seems to be the result of the long-term 
adequate basic therapy. The patient subgroups were similar in 
terms of lung ventilation function measured as FEV1. This can 
be explained by the fact that initially both subgroups included 
patients with ventilation disorders varying from stage 2 to 
stage 4 according to the GOLD classification [8]. 
Analysis of severity of COPD symptoms showed that at 
baseline both patient subgroups were similar in their dyspnea 
levels as assessed with the mMRC scale, however the 
subgroups were different in terms of severity of symptoms 
according to the CAT and SGRQ scores (the 'symptoms' 
domain). This may be due to the fact that the CAT and SGRQ 
scores are more focused on COPD symptoms while mMRC 
scale only measures dyspnea levels. Patients in subgroup 2 
had significantly higher severity of COPD symptoms than 
those in subgroup 1. This lower severity of symptoms in 
subgroup 1 seems to be the result of the long-term adequate 
basic therapy (see Table 1). 
 
Table 1: Comparison of symptoms severity and severity of systemic inflammation between subgroups at visit 1 
 
Variables Subgroup 1 (n=20) visit 1 Subgroup 2 (n=17) visit 1 р 
mMRC (score) 1 [1–2] 1 [1–3] 0,502 
САТ (score) 15 [11–20] 20 [13–27] 0,021 
SGRQ (domain ‘symptoms’) 44,1 [34,2–59,2] 63,2 [50,1–81,7] 0,031 
CRP (mg/l) 4,04 [3,72‒4,83] 11,30 [9,0‒16,60] 0,000 
САА (ng/l) 220,97 [192,75‒247,52] 666,66 [345,63‒1346,15] 0,000 
 
It was also found that in subgroup 2 baseline systemic 
inflammation levels measured by both (CRP and SAA) study 
markers were significantly higher than in subgroup 1, which 
may indicate positive effects of the long-term adequate 
therapy on systemic inflammation in COPD patients (see 
Table 1). It should be noted that in subgroup 2 baseline 
systemic inflammation markers were roughly three times 
higher than in subgroup 1. 
At the next stage, we compared changes in severity of 
systemic inflammation symptoms in both patient groups. 
It was established that COPD symptoms levels in subgroup 1 
assessed by the mMRC, CAT and SGRQ scores (the 
'symptoms' domain) did not change significantly.  
FEV1 in subgroup 1 did not show any significant changes and 
was 45.1[41‒58.9] (p=0.301 vs Visit 1). 
Analysis of changes in systemic inflammation markers 
showed that at Visit 2 CRP levels in subgroup 1 were 
significantly lower than at baseline. It should also be noted 
that CRP levels in patients who received long-term adequate 
therapy were lower than standard reference values and close 
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to 3 mg/mL, which can be a favourable predictive index (see 
Table 2) as some studies showed that COPD patients with 
relatively high CRP levels (> 3 mg/mL) have higher hospital 
admission and mortality rates than patients with CRP levels 
< 3 mg/mL [11]. No similar significant changes in SAA levels 
were found in subgroup 1 (see Table 2). SAA seems not to 
respond to prescribed treatment, and there is evidence that, 
unlike CRP, SAA levels are lowered even by 
immunosuppressive (including corticosteroid) therapy [14]. 
 
Table 2: Dynamics of symptoms severity and markers of systemic inflammation in patients of subgroup 1 
 
Variables Subgroup 1 (n=20) visit 1 visit 2 р 
mMRC (score) 1 [1–2] 1 [1–2] 0,248 
САТ (score) 15 [11–20] 12 [10–16] 0,214 
SGRQ (domain ‘symptoms’) 44,1 [34,2–59,2] 36,7 [27,8–43,3] 0,151 
CRP (mg/l) 4,04 [3,72‒4,83] 3,24 [2,49‒3,81] 0,024 
САА (ng/l) 220,97 [192,75‒247,52] 220,36 [175,42‒279,83] 0,479 
 
The adjustment in subgroup 2 therapy according to the 
severity of the condition was accompanied by a statistically 
significant decrease in severity of COPD symptoms assessed 
by the CAT and SGRQ scores while dyspnea levels measured 
by the mMRC scale remained the same (see Table 3). 
 
Table 3: Dynamics of symptoms severity and markers of systemic inflammation in patients of subgroup 2 
 
Variables Subgroup 2 (n=17) visit 1 visit 2 р 
mMRC (score) 1 [1–3] 1 [1–2] 0,479 
САТ (score) 20 [13–27] 15 [12–18] 0,003 
SGRQ (domain ‘symptoms’) 63,2 [50,1–81,7] 38,6 [31,7–46,5] 0,041 
CRP (mg/l) 11,30 [9,0‒16,60] 4,90 [4,32‒6,87] 0,001 
САА (ng/l) 666,66 [345,63‒1346,15] 317,79 [217,34‒1179,49] 0,772 
 
At Visit 2, FEV1 level in subgroup 2 was 43.5[39.5–59.0] 
(p=0.789 vs Visit 1), therefore, no statistically significant 
improvement in FEV1 was noted in Group 2 during the study 
period. 
As for severity of systemic inflammation in subgroup 2, after 
three months of adequate therapy (at Visit 2) CRP levels were 
significantly lower than at baseline (see Table 3). At the same 
time, SAA changes median in subgroup 2 was nearly twice 
lower but statistically insignificant, unlike PSA. It should be 
noted, given these data, that SAA is much slower to respond 
to therapy, which is not the case with CRP. This means that 
systemic inflammation severity assessment only by CRP 
levels may be insufficient. 
Comparison of COPD symptoms and systemic inflammation 
levels in both patient subgroups at Visit 2 showed that 
symptoms in subgroup 2 reached subgroup 1 levels after three 
months of adequate therapy. The Mann-Whitney U test was 
used to compare the two patient groups at Visit 2 by dyspnea 
levels as assessed with the mMRC scale (p=0.236 in the 
patient groups at Visit 2), and severity of COPD symptoms 
measured with the CAT score (p=0.267) and the SGRQ score 
(the 'symptoms' domain) (p=0.643)). 
Though patients in subgroup 2 had been receiving three-
month COPD treatment adequate to their condition, systemic 
inflammation decreased significantly in such patients yet 
remained higher than in subgroup 1. CRP and SAA levels in 
subgroup 2 remained higher that in subgroup 1 (p=0.011, 
p=0.023, respectively) (see Table 2, 3). A longer period of 
adequate therapy seems to be needed for a more significant 
improvement of systemic inflammation. 
 
4. Conclusion 
1. If treated inadequately, COPD patients in the stable 
phase, regardless of severity of their condition, suffer 
from more intense symptoms, have more relapses over 
the previous year, and their systemic inflammation levels 
are higher than in patients who receive long-term therapy 
adequate to their COPD. 
2. Proper three-month COPD treatment helps improve the 
symptoms to the levels found in patients who receive 
longer adequate therapy. 
3. As soon as three months after initiation, correctly 
assigned COPD treatment helps reduce systemic 
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